Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 6/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.46 |
| ▸ | PDE4A | P27815 | 2/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.45 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1667168 | 0.94 | GPR119 (0.55) | TBK1GPR119PDE4BPDE4APDE4C | |
| SCHEMBL17631454 | 0.91 | AAK1 (0.46) | TBK1GPR119PDE4BUSP30AAK1 | |
| SCHEMBL17645008 | 0.89 | AAK1 (0.45) | TBK1GPR119PDE4BUSP30IKBKE | |
| SCHEMBL38660667 | 0.88 | PDE4B (0.47) | TBK1GPR119PDE4BUSP30PIK3CD | |
| SCHEMBL16853884 | 0.86 | TBK1 (0.52) | TBK1GPR119PDE4BUSP30IKBKE | |
| SCHEMBL17630550 | 0.86 | TBK1 (0.52) | TBK1GPR119PDE4BUSP30IKBKE | |
| SCHEMBL17631334 | 0.86 | TBK1 (0.52) | TBK1GPR119PDE4BUSP30IKBKE | |
| SCHEMBL16853568 | 0.86 | TBK1 (0.52) | TBK1GPR119PDE4BUSP30IKBKE | |
| SCHEMBL16792965 | 0.85 | GPR119 (0.52) | TBK1GPR119PDE4BUSP30PIK3CD | |
| SCHEMBL16792922 | 0.85 | GPR119 (0.52) | TBK1GPR119PDE4BUSP30PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988391-B2 | TBK/IKK inhibitor compounds and uses thereof | MERCK PATENT GMBH (DE) | 2018-06-05 | — | — | US | disclosed |
| WO-2017003995-A1 | TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-01-05 | — | — | WO | disclosed |
| US-20160376283-A1 | TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376283-A1 | TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF | NFKBIA, TBKBP1, TBK1 | TBK1 3/4885GPR119 1219/4885PDE4B 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.